2022 Portfolio Review -A Quick Look Back, Then Start Looking Forward

My annual investment review for 2022. This year has been a rollercoaster for the stock market, here are the key takeaways from my portfolio.

Haw Par Group (SGX:H02) – A Simple Analysis II

I covered Haw Par Group back in 2019. Hence I think it is time to revisit this company which is trading at multi year lows.

A valuable read for investors looking to improve their decision-making skills in the stock market.

Discover the potential of investing in Medpace Holdings Inc ($MEDP), a leading global CROin the healthcare industry.

Navigating the stock market: comparing the pros and cons of dollar cost averaging and lump sum investing. Which is right strategy for you?

Books can be a useful resource for investors. Here are the 3 books that got me started in value investing.

Pages: 1 2

We study uniQure NV ($QURE), a biotechnology company focused on developing gene therapies for rare diseases.

VolitionRx is commercially introducing a product with a huge addressable market. If successful, the market will rerate the stock.

SOTP valuation shows Boustead's share price is undervalued. However, there may be a lack of near term catalyst for a rerate of share price.

I will be discussing the individual superinvestors mentioned in the article "The Superinvestors of Graham-and-Doddsville,". This article was published in 1984 by Warren Buffett in the Hermes Society Newsletter. Here is a link to the article: https://www8.gsb.columbia.edu/articles/columbia-business/superinvestors Summary "The Superinvestors of Graham-and-Doddsville" was written by Warren Buffett in 1984. In the article, Buffett discusses the … Continue reading The 7 Superinvestors Featured in “Superinvestors of Graham & Doddsville” by Warren Buffet